nach oben

Erschienen in:

01.08.2014 | SHORT REPORT

Kidney injuries related to ipilimumab

verfasst von: Hassane Izzedine, Victor Gueutin, Chems Gharbi, Christine Mateus, Caroline Robert, Emilie Routier, Marina Thomas, Alain Baumelou, Philippe Rouvier

Erschienen in: Investigational New Drugs | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Summary

Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called “immune-related adverse events” (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCentralCrossRefPubMed

Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci 100:4712–4717PubMedCentralCrossRefPubMed

Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der SD, Kang J, Chambers CA (2009) CD4+ Regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206:421–434PubMedCentralCrossRefPubMed

Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Thompson J, Fulcher D, Kefford R (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29:e237–e240CrossRefPubMed

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8:e537–545CrossRef

Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283–2289PubMedCentralCrossRefPubMed

Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:211–212CrossRefPubMed

Forde PM, Rock K, Wilson G, O’Byrne KJ (2012) Ipilimumab-induced immune-related renal failure—a case report. Anticancer Res 32:4607–4608PubMed

Lebbe C, O’Day S, Chiarion Sileni V, Gajewski T, Pehamberger H, Bondarenko I, Queirolo P, Lundgren S, Roman L, Verschraegen C, Ibrahim R, Chin K, Hoos A, Maio M (2008). Analysis of the onset and resolution of immune related adverse events during treatment with ipilimumab in patients with metastatic melanoma. (oral abstract O-015, Perspectives in Melanoma XII).

10.

Haas M, Spargo BH, Wit EJ, Meehan SM (2000) Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 35:433–447CrossRefPubMed

11.

Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ (2006) Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 17:2919–2927CrossRefPubMed

12.

Clarkson MR, Giblin L, O’Connell FP, O’Kelly P, Walshe JJ, Conlon P, O’Meara Y, Dormon A, Campbell E, Donohoe J (2004) Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 19:2778–2783CrossRefPubMed

13.

Bhaumik SK, Kher V, Arora P, Rai PK, Singhal M, Gupta A, Pandey R, Sharma RK (1996) Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Ren Fail 18:97–104CrossRefPubMed

14.

Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A (2000) The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 54:179–190PubMed

15.

Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, Binder M (2011) Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 28:1140–1144CrossRefPubMed

16.

Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P, Liu Y (2005) Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106:3127–3133PubMedCentralCrossRefPubMed

17.

Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27:68–73CrossRefPubMed

18.

Bennett CL, Ochs HD (2001) IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr 13:533–538CrossRefPubMed

19.

Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20–21CrossRefPubMed

20.

Liu SM, Sutherland AP, Zhang Z, Rainbow DB, Quintana FJ, Paterson AM, Sharpe AH, Oukka M, Wicker LS, Kuchroo VK (2012) Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity. J Immunol 188:155–162PubMedCentralCrossRefPubMed

21.

Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG (2001) Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166:6430–6436CrossRefPubMed

22.

Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T (1999) Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 162:4328–4335PubMed

Titel: Kidney injuries related to ipilimumab
verfasst von: Hassane Izzedine
Victor Gueutin
Chems Gharbi
Christine Mateus
Caroline Robert
Emilie Routier
Marina Thomas
Alain Baumelou
Philippe Rouvier
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 4/2014
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-014-0092-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Kidney injuries related to ipilimumab

Summary

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries

Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie